webinar
Exploring the critical roles of astrocytes in health and disease
31 July 2024 | By bit.bio
Watch this webinar to discover the latest astrocyte research and its implications for CNS drug discovery.
List view / Grid view
Drug Discovery Processes
news
Mini-lungs enable breakthroughs in SARS-CoV-2 research
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
article
The power of big data to advance genomics into clinical care
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
webinar
Rapid functional cell-based activity profiling of multi-receptor targeted anti-obesity therapies
25 July 2024 | By Eurofins Discovery
Eurofins Discovery’s Luke Oostdyk, PhD, will highlight anti-obesity target combination therapies and cell-based assays ideal for testing functional activity, specificity, potency and signalling mechanisms of desired therapies against multiple disease-relevant targets.
news
New model offers a unique method to study Parkinson’s disease
Mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models.
article
Part three: pragmatic guidelines to getting the best out of LLMs
There have been a slew of announcements over the past few months from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the third of a three-part series, Dr Raminderpal Singh presents some pragmatic guidelines for scientists in accessing and obtaining value from LLMs.
webinar
CRISPR™ MDCKII cell lines development for bioavailability and DDI assessments
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
news
Elucidating the loss of mobility caused by LGMD2B
The hiPSC-derived skeletal muscle model is the first to uncover the biological mechanisms underlying loss of mobility.
news
Novel inhibitor developed to combat HER2-positive breast cancer
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
news
The potential of deep learning: generating drug targets
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
article
Changing the paradigm of drug discovery processes with AI
We had the privilege of speaking to Cellarity’s CEO, Fabrice Chouraqui, about how the company is leveraging AI to completely revolutionise the drug discovery process and unlock treatments for a vast array of diseases, even in the absence of known targets.
article
Part one: what can scientists do with LLMs today?
Recently there have been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the first of a three-part series, Dr Raminderpal Singh explores what LLMs are, how early stage biotechs can take advantage of them, and what challenges they…
news
Mini-colons offer improved cellular diversity, longevity and function
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
podcasts
Small molecules for regenerative medicine
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
news
Essential insights into HIV-1 latency mechanisms
HIV-Tocky, a new viral reporter system, uncovers the molecular mechanisms of provirus silencing and expression.